NASDAQ:RUBY - Rubius Therapeutics News Headlines

$9.98
+0.45 (+4.72 %)
(As of 09/16/2019 12:23 PM ET)
Today's Range
$9.37
Now: $9.98
$10.00
50-Day Range
$8.75
MA: $10.89
$14.31
52-Week Range
$8.54
Now: $9.98
$24.49
Volume3,134 shs
Average Volume239,480 shs
Market Capitalization$794.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.25

Headlines

Rubius Therapeutics (NASDAQ RUBY) News Headlines

Source:
DateHeadline
Rubius Therapeutics (NASDAQ:RUBY) Now Covered by Analysts at Robert W. BairdRubius Therapeutics (NASDAQ:RUBY) Now Covered by Analysts at Robert W. Baird
www.americanbankingnews.com - September 9 at 8:39 PM
-$0.53 EPS Expected for Rubius Therapeutics Inc (NASDAQ:RUBY) This Quarter-$0.53 EPS Expected for Rubius Therapeutics Inc (NASDAQ:RUBY) This Quarter
www.americanbankingnews.com - September 8 at 4:23 AM
Rubius Therapeutics Inc (NASDAQ:RUBY) Given Average Recommendation of "Buy" by BrokeragesRubius Therapeutics Inc (NASDAQ:RUBY) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 6 at 4:41 AM
JPMorgan Chase & Co. Lowers Rubius Therapeutics (NASDAQ:RUBY) Price Target to $22.00JPMorgan Chase & Co. Lowers Rubius Therapeutics (NASDAQ:RUBY) Price Target to $22.00
www.americanbankingnews.com - August 29 at 8:56 AM
Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational ProgressRubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
finance.yahoo.com - August 13 at 9:12 AM
Rubius Therapeutics to Announce Second Quarter 2019 Financial ResultsRubius Therapeutics to Announce Second Quarter 2019 Financial Results
finance.yahoo.com - August 7 at 7:03 PM
Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and StrategyRubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy
finance.yahoo.com - July 25 at 2:06 PM
Investors Who Bought Rubius Therapeutics (NASDAQ:RUBY) Shares A Year Ago Are Now Down 44%Investors Who Bought Rubius Therapeutics (NASDAQ:RUBY) Shares A Year Ago Are Now Down 44%
finance.yahoo.com - July 19 at 6:30 PM
Rubius Therapeutics (RUBY) Presents At Jefferies 2019 Healthcare Conference - SlideshowRubius Therapeutics (RUBY) Presents At Jefferies 2019 Healthcare Conference - Slideshow
seekingalpha.com - June 7 at 4:01 PM
Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic ProgramsRubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs
finance.yahoo.com - June 5 at 11:40 AM
Rubius Therapeutics to Present at Jefferies 2019 Healthcare ConferenceRubius Therapeutics to Present at Jefferies 2019 Healthcare Conference
finance.yahoo.com - May 29 at 11:29 AM
Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational ProgressRubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
finance.yahoo.com - May 15 at 11:48 AM
Rubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual MeetingRubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 2 at 11:23 AM
Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business UpdatesRubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates
finance.yahoo.com - March 28 at 12:49 PM
How Many Insiders Bought Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?How Many Insiders Bought Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
finance.yahoo.com - March 26 at 12:27 PM
Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality OfficerRubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer
finance.yahoo.com - March 25 at 12:00 PM
Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial ResultsRubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results
finance.yahoo.com - March 20 at 11:42 AM
Rubius Therapeutics, Inc. Estimate MomentumRubius Therapeutics, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 3:59 PM
Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of PhenylketonuriaRubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
finance.yahoo.com - March 11 at 8:49 AM
Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual MeetingRubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting
finance.yahoo.com - February 28 at 12:25 PM
Rubius Therapeutics to Participate at Upcoming Investor ConferencesRubius Therapeutics to Participate at Upcoming Investor Conferences
finance.yahoo.com - February 20 at 12:13 PM
TCR2, Avedro wrangle $145M in first life science IPOs of 2019TCR2, Avedro wrangle $145M in first life science IPOs of 2019
www.bizjournals.com - February 14 at 3:39 PM
Rubius Therapeutics (RUBY) Presents At 37th Annual J.P. Morgan Healthcare Conference - SlideshowRubius Therapeutics (RUBY) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 9 at 3:34 PM
Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare ConferenceRubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 10:59 AM
Biotechs dominate largest IPOs among Mass. companies in 2018Biotechs dominate largest IPOs among Mass. companies in 2018
www.bizjournals.com - December 27 at 10:18 AM
Rubius Therapeutics, Inc. Secures $75 Million Loan FacilityRubius Therapeutics, Inc. Secures $75 Million Loan Facility
finance.yahoo.com - December 21 at 3:27 PM
Rubius Therapeutics Inc.Rubius Therapeutics Inc.
www.barrons.com - December 19 at 3:29 PM
Rubius Therapeutics Added to Nasdaq Biotechnology IndexRubius Therapeutics Added to Nasdaq Biotechnology Index
finance.yahoo.com - December 18 at 9:53 AM
Qatar Fund Building Venture Capital Unit for U.S. StartupsQatar Fund Building Venture Capital Unit for U.S. Startups
finance.yahoo.com - December 16 at 9:30 AM
Flagship Pioneering Names Ryan Watts, CEO of Denali Therapeutics, as Recipient of the 2018 Pioneering Leader AwardFlagship Pioneering Names Ryan Watts, CEO of Denali Therapeutics, as Recipient of the 2018 Pioneering Leader Award
www.bizjournals.com - November 15 at 3:22 PM
Rubius Therapeutics Reports Third Quarter 2018 Financial Results and Operational ProgressRubius Therapeutics Reports Third Quarter 2018 Financial Results and Operational Progress
finance.yahoo.com - November 13 at 3:23 PM
Rubius Therapeutics to Participate in Jefferies London Healthcare ConferenceRubius Therapeutics to Participate in Jefferies London Healthcare Conference
finance.yahoo.com - November 7 at 8:11 AM
Rubius Therapeutics to Announce Third Quarter 2018 Financial ResultsRubius Therapeutics to Announce Third Quarter 2018 Financial Results
finance.yahoo.com - November 6 at 7:56 AM
Rubius (RUBY) in Focus: Stock Moves 8.7% HigherRubius (RUBY) in Focus: Stock Moves 8.7% Higher
finance.yahoo.com - September 24 at 3:18 PM
Biotech Market is Rolling and These Companies Need to Be on Your RadarBiotech Market is Rolling and These Companies Need to Be on Your Radar
finance.yahoo.com - September 24 at 3:18 PM
Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-OncologyRubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
finance.yahoo.com - September 21 at 6:54 AM
Rubius Therapeutics Added to Russell 2000 and 3000 IndexesRubius Therapeutics Added to Russell 2000 and 3000 Indexes
finance.yahoo.com - September 15 at 6:31 AM
How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic DiseaseHow This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease
finance.yahoo.com - September 6 at 6:16 AM
What you missed on your summer vacation in Mass. biotech newsWhat you missed on your summer vacation in Mass. biotech news
finance.yahoo.com - September 4 at 6:37 AM
Rubius Therapeutics reports Q2 resultsRubius Therapeutics reports Q2 results
seekingalpha.com - August 31 at 3:17 PM
Rubius Therapeutics to Announce Second Quarter 2018 Financial ResultsRubius Therapeutics to Announce Second Quarter 2018 Financial Results
finance.yahoo.com - August 22 at 6:06 AM
Rubius Therapeutics Inc. (RUBY) Prices 10.48M Share IPO at $23/ShRubius Therapeutics Inc. (RUBY) Prices 10.48M Share IPO at $23/Sh
www.streetinsider.com - August 3 at 5:27 AM
Rubius Therapeutics (RUBY) Agrees to Acquire Manufacturing Facility in Smithfield, Rhode IslandRubius Therapeutics (RUBY) Agrees to Acquire Manufacturing Facility in Smithfield, Rhode Island
www.streetinsider.com - July 30 at 3:15 PM
Rubius to acquire Rhode Island manufacturing siteRubius to acquire Rhode Island manufacturing site
seekingalpha.com - July 27 at 8:43 AM
Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell TherapeuticsRubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics
finance.yahoo.com - July 27 at 8:43 AM
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel